Pancreatic Cancer: A Review on Pathophysiology, Naturopathy, Clinical
Treatment and Outcomes

Rituraj      Chakraborty; Anupam      Dutta; Bhargab   Jyoti   Baruah; Rajni      Kumari; Priyanku      Sarma; Ankita      Sharma; Krishangi      Goswami; Haritha      Myakala; Akalesh   Kumar   Verma
doi:10.2174/1573394719666230830125213
Abstract

The study aimed to comprehend the molecular mechanisms and pathophysiology of pancreatic cancer with an emphasis on the advances in treatment options and the use of natural products as anticancer agents. The study involved a literature survey using PubMed, Web of Science and Google scholar database. The literature search was done using keywords “Pancreatic cancer”, “Chemotherapy”, “Mutations”, and “Natural compounds”. 266 articles were studied of which 201 were taken into consideration based on relevance to the topic. Pancreatic cancer is associated with mutations of CDKN2A (encoding p16), KRAS, TP53 and SMAD4. MAPK, PI3K-AKT, and TGF- β pathway dysfunction also led to pancreatic cancer. Current clinical trial activities in pancreatic cancer target angiogenesis, surface receptors, cell cycle, DNA damage response, etc. Studies have shown that combining surgical resection with adjuvant chemotherapy increases survival rates in patients. New treatment options are on the rise for this cancer type, which is perioperative or neo-adjuvant therapy. Gemcitabine as a single treatment agent in pancreatic cancer has shown promising response with chemotherapy regimens using two combinations- Folfirinox and Gemcitabine/Nab-Paclitaxel giving a better response rate. Numerous natural substances, including curcumin, aloe vera, and taxol, which suppress oxidative stress, angiogenesis, JAK2 STAT3 pathways, and enhanced natural killer cell activity, have been explored as potential treatments for pancreatic cancer. With pancreatic cancer having a poor prognosis, investigations to comprehend its molecular underpinnings and research on natural chemicals could lead to the development of safer treatment alternatives with enhanced survival rates for pancreatic cancer patients.
Keywords: Cancer biomarkers, chemotherapy, clinical trials, curcumin, mutations, molecular pathophysiology.
« Previous Next »
Graphical Abstract

[1]
Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet  2016; 388(10039): 73-85.
 [http://dx.doi.org/10.1016/S0140-6736(16)00141-0] [PMID:  26830752]

[2]
Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer  2002; 2(12): 897-909.
 [http://dx.doi.org/10.1038/nrc949] [PMID:  12459728]

[3]
Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut  2007; 56(8): 1134-52.
 [PMID:  17625148]

[4]
Kern SE, Hruban RH, Hidalgo M, Yeo CJ. An introduction to pancreatic adenocarcinoma genetics, pathology and therapy. Cancer Biol Ther  2002; 1(6): 607-13.
 [http://dx.doi.org/10.4161/cbt.307] [PMID:  12642681]

[5]
Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet  2004; 363(9414): 1049-57.
 [http://dx.doi.org/10.1016/S0140-6736(04)15841-8] [PMID:  15051286]

[6]
Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol  2019; 10(1): 10-27.
 [http://dx.doi.org/10.14740/wjon1166] [PMID:  30834048]

[7]
Parkin DM, Boyd L, Walker LC. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J Cancer  2011; 105 (Suppl. 2): S77-81.

[8]
Hidalgo M. Pancreatic Cancer. N Engl J Med  2010; 362(17): 1605-17.
 [http://dx.doi.org/10.1056/NEJMra0901557] [PMID:  20427809]

[9]
Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA  2009; 301(24): 2553-62.
 [http://dx.doi.org/10.1001/jama.2009.886] [PMID:  19549972]

[10]
Lightsey D. Comment on ‘Red and processed meat consumption and risk of pancreatic cancer: Meta-analysis of prospective studies’. Br J Cancer  2012; 107(4): 754-5.
 [http://dx.doi.org/10.1038/bjc.2012.111] [PMID:  22805322]

[11]
Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol  2006; 20(2): 197-209.
 [http://dx.doi.org/10.1016/j.bpg.2005.10.001] [PMID:  16549324]

[12]
Wolpin BM, Chan AT, Hartge P, et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst  2009; 101(6): 424-31.
 [http://dx.doi.org/10.1093/jnci/djp020] [PMID:  19276450]

[13]
Hakomori S. Antigen structure and genetic basis of histo-blood groups A, B and O: Their changes associated with human cancer. Biochim Biophys Acta, Gen Subj  1999; 1473(1): 247-66.
 [http://dx.doi.org/10.1016/S0304-4165(99)00183-X] [PMID:  10580143]

[14]
Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. Nat Rev Dis Primers  2016; 2(1): 16022.
 [http://dx.doi.org/10.1038/nrdp.2016.22] [PMID:  27158978]

[15]
Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: Deleterious BRCA2 mutations in 17%. Cancer Res  2002; 62(13): 3789-93.
 [PMID:  12097290]

[16]
Slater EP, Langer P, Niemczyk E, et al. PALB2 mutations in European familial pancreatic cancer families. Clin Genet  2010; 78(5): 490-4.
 [http://dx.doi.org/10.1111/j.1399-0004.2010.01425.x] [PMID:  20412113]

[17]
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet  2011; 378(9791): 607-20.
 [http://dx.doi.org/10.1016/S0140-6736(10)62307-0] [PMID:  21620466]

[18]
Hirayama T. Epidemiology of pancreatic cancer in Japan. Jpn J Clin Oncol  1989; 19(3): 208-15.
 [PMID:  2810821]

[19]
Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol  2016; 22(44): 9694-705.
 [http://dx.doi.org/10.3748/wjg.v22.i44.9694] [PMID:  27956793]

[20]
Yeo TP, Lowenfels AB. Demographics and epidemiology of pancreatic cancer. Cancer J  2012; 18(6): 477-84.
 [http://dx.doi.org/10.1097/PPO.0b013e3182756803] [PMID:  23187833]

[21]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer  2015; 136(5): E359-86.
 [http://dx.doi.org/10.1002/ijc.29210] [PMID:  25220842]

[22]
Longnecker DS, Karagas MR, Tosteson TD, Mott LA. Racial differences in pancreatic cancer: Comparison of survival and histologic types of pancreatic carcinoma in Asians, blacks, and whites in the United States. Pancreas  2000; 21(4): 338-43.
 [http://dx.doi.org/10.1097/00006676-200011000-00003] [PMID:  11075987]

[23]
Lynch HT, Deters CA, Lynch JF, Brand RE. Familial pancreatic carcinoma in Jews. Fam Cancer  2004; 3(3-4): 233-40.
 [http://dx.doi.org/10.1007/s10689-004-9549-8] [PMID:  15516847]

[24]
Alghamdi IG, Almadi M, Alsohaibani F, et al. Epidemiology of Pancreatic Cancer in Saudi Arabia: A Retrospective Analysis of Pancreatic Cancer Diagnosed in Saudi Arabia Between 2004 and 2015. Clin Exp Gastroenterol  2021; 14: 45-57.
 [http://dx.doi.org/10.2147/CEG.S289269] [PMID:  33603433]

[25]
Haidinger G. Epidemiology of Pancreatic Cancer Textbook of Pancreatic Cancer.  Heidelberg: Springer 2021; pp. 17-27.
 [http://dx.doi.org/10.1007/978-3-030-53786-9_2]

[26]
Pourshams A, Sepanlou SG, Ikuta KS, et al. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol  2019; 4(12): 934-47.
 [http://dx.doi.org/10.1016/S2468-1253(19)30347-4] [PMID:  31648972]

[27]
Klein AP. Pancreatic cancer epidemiology: Understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol  2021; 18(7): 493-502.
 [http://dx.doi.org/10.1038/s41575-021-00457-x] [PMID:  34002083]

[28]
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer  2018; 103: 356-87.
 [http://dx.doi.org/10.1016/j.ejca.2018.07.005] [PMID:  30100160]

[29]
Hawksworth G, Hales J, Martinez F, Hynes A, Hamilton A, Fernandez V. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Med Stud  2019; 35(2): 164-71.

[30]
Gaidhani RH, Balasubramaniam G. An epidemiological review of pancreatic cancer with special reference to India. Indian J Med Sci  2021; 73(1): 99-109.
 [http://dx.doi.org/10.25259/IJMS_92_2020]

[31]
Hu JX, Zhao CF, Chen WB, et al. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J Gastroenterol  2021; 27(27): 4298-321.
 [http://dx.doi.org/10.3748/wjg.v27.i27.4298] [PMID:  34366606]

[32]
Ranganath R, Chu Q. Global trends in pancreas cancer among Asia-Pacific population. J Gastrointest Oncol  2021; 12(S2) (Suppl. 2): S374-86.
 [http://dx.doi.org/10.21037/jgo-20-118] [PMID:  34422401]

[33]
McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol  2018; 24(43): 4846-61.
 [http://dx.doi.org/10.3748/wjg.v24.i43.4846] [PMID:  30487695]

[34]
Luo J, Iwasaki M, Inoue M, et al. Body mass index, physical activity and the risk of pancreatic cancer in relation to smoking status and history of diabetes: A large-scale population-based cohort study in Japan–The JPHC study. Cancer Causes Control  2007; 18(6): 603-12.
 [http://dx.doi.org/10.1007/s10552-007-9002-z] [PMID:  17401636]

[35]
Bosetti C, Lucenteforte E, Silverman DT, et al. Cigarette smoking and pancreatic cancer: An analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol  2012; 23(7): 1880-8.
 [http://dx.doi.org/10.1093/annonc/mdr541] [PMID:  22104574]

[36]
Neureiter D, Jäger T, Ocker M, Kiesslich T. Epigenetics and pancreatic cancer: Pathophysiology and novel treatment aspects. World J Gastroenterol  2014; 20(24): 7830-48.
 [http://dx.doi.org/10.3748/wjg.v20.i24.7830] [PMID:  24976721]

[37]
Haeberle L, Esposito I. Pathology of pancreatic cancer. Transl Gastroenterol Hepatol  2019; 4: 50.
 [http://dx.doi.org/10.21037/tgh.2019.06.02] [PMID:  31304427]

[38]
Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell  2005; 7(5): 469-83.
 [http://dx.doi.org/10.1016/j.ccr.2005.04.023] [PMID:  15894267]

[39]
Buchholz M, Kestler HA, Bauer A, et al. Specialized DNA arrays for the differentiation of pancreatic tumors. Clin Cancer Res  2005; 11(22): 8048-54.
 [http://dx.doi.org/10.1158/1078-0432.CCR-05-1274] [PMID:  16299235]

[40]
Xu S, Furukawa T, Kanai N, Sunamura M, Horii A. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J Hum Genet  2005; 50(4): 159-67.
 [http://dx.doi.org/10.1007/s10038-005-0235-y] [PMID:  15824892]

[41]
Saiki Y, Horii A. Molecular pathology of pancreatic cancer. Pathol Int  2014; 64(1): 10-9.
 [http://dx.doi.org/10.1111/pin.12114] [PMID:  24471965]

[42]
Bardeesy N, Aguirre AJ, Chu GC, et al. Both p16 Ink4a and the p19 Arf -p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA  2006; 103(15): 5947-52.
 [http://dx.doi.org/10.1073/pnas.0601273103] [PMID:  16585505]

[43]
Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med  2004; 10(8): 789-99.
 [http://dx.doi.org/10.1038/nm1087] [PMID:  15286780]

[44]
Iacobuzio-Donahue CA, Song J, Parmiagiani G, Yeo CJ, Hruban RH, Kern SE. Missense Mutations of MADH4. Clin Cancer Res  2004; 10(5): 1597-604.
 [http://dx.doi.org/10.1158/1078-0432.CCR-1121-3] [PMID:  15014009]

[45]
Corbo V, Tortora G, Scarpa A. Molecular pathology of pancreatic cancer: From bench-to-bedside translation. Curr Drug Targets  2012; 13(6): 744-52.
 [http://dx.doi.org/10.2174/138945012800564103] [PMID:  22458520]

[46]
Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: A new marker of DPC4 inactivation. Am J Pathol  2000; 156(1): 37-43.
 [http://dx.doi.org/10.1016/S0002-9440(10)64703-7] [PMID:  10623651]

[47]
Erkan M, Reiser-Erkan C, Michalski CW, et al. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia  2009; 11(5): 497-508.
 [http://dx.doi.org/10.1593/neo.81618] [PMID:  19412434]

[48]
Infante JR, Matsubayashi H, Sato N, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol  2007; 25(3): 319-25.
 [http://dx.doi.org/10.1200/JCO.2006.07.8824] [PMID:  17235047]

[49]
Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res  2007; 67(3): 1030-7.
 [http://dx.doi.org/10.1158/0008-5472.CAN-06-2030] [PMID:  17283135]

[50]
Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell  2009; 139(5): 871-90.
 [http://dx.doi.org/10.1016/j.cell.2009.11.007] [PMID:  19945376]

[51]
Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy. Expert Opin Ther Targets  2012; 16(1): 103-19.
 [http://dx.doi.org/10.1517/14728222.2011.645805] [PMID:  22239440]

[52]
Furukawa T. Impacts of activation of the mitogen-activated protein kinase pathway in pancreatic cancer. Front Oncol  2015; 5: 23.
 [http://dx.doi.org/10.3389/fonc.2015.00023] [PMID:  25699241]

[53]
Knight T, Irving JAE. Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting. Front Oncol  2014; 4: 160.
 [http://dx.doi.org/10.3389/fonc.2014.00160] [PMID:  25009801]

[54]
Cseh B, Doma E, Baccarini M. “RAF” neighborhood: Protein-protein interaction in the Raf/Mek/Erk pathway. FEBS Lett  2014; 588(15): 2398-406.
 [http://dx.doi.org/10.1016/j.febslet.2014.06.025] [PMID:  24937142]

[55]
Chappell WH, Steelman LS, Long JM, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: Rationale and importance to inhibiting these pathways in human health. Oncotarget  2011; 2(3): 135-64.
 [http://dx.doi.org/10.18632/oncotarget.240] [PMID:  21411864]

[56]
Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med  2012; 10(1): 85.
 [http://dx.doi.org/10.1186/1479-5876-10-85] [PMID:  22554099]

[57]
Vara JÁF, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev  2004; 30(2): 193-204.
 [http://dx.doi.org/10.1016/j.ctrv.2003.07.007] [PMID:  15023437]

[58]
Jiang N, Dai Q, Su X, Fu J, Feng X, Peng J. Role of PI3K/AKT pathway in cancer: The framework of malignant behavior. Mol Biol Rep  2020; 47(6): 4587-629.
 [http://dx.doi.org/10.1007/s11033-020-05435-1] [PMID:  32333246]

[59]
Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E. PI3K/AKT signaling pathway and cancer: An updated review. Ann Med  2014; 46(6): 372-83.
 [http://dx.doi.org/10.3109/07853890.2014.912836] [PMID:  24897931]

[60]
Murthy D, Attri KS, Singh PK. Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics. Front Physiol  2018; 9: 335.
 [http://dx.doi.org/10.3389/fphys.2018.00335] [PMID:  29670543]

[61]
Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene  2005; 24(50): 7455-64.
 [http://dx.doi.org/10.1038/sj.onc.1209085] [PMID:  16288292]

[62]
Syed V. TGF-β Signaling in Cancer. J Cell Biochem  2016; 117(6): 1279-87.
 [http://dx.doi.org/10.1002/jcb.25496] [PMID:  26774024]

[63]
Wakefield LM, Hill CS. Beyond TGFβ: Roles of other TGFβ superfamily members in cancer. Nat Rev Cancer  2013; 13(5): 328-41.
 [http://dx.doi.org/10.1038/nrc3500] [PMID:  23612460]

[64]
Chen W, ten Dijke P. Immunoregulation by members of the TGFβ superfamily. Nat Rev Immunol  2016; 16(12): 723-40.
 [http://dx.doi.org/10.1038/nri.2016.112] [PMID:  27885276]

[65]
Gu S, Feng XH. TGF-β signaling in cancer. Acta Biochim Biophys Sin (Shanghai)  2018; 50(10): 941-9.
 [http://dx.doi.org/10.1093/abbs/gmy092] [PMID:  30165534]

[66]
Sancho P, Alcala S, Usachov V, Hermann PC, Sainz B Jr. The ever-changing landscape of pancreatic cancer stem cells. Pancreatology  2016; 16(4): 489-96.

[67]
Li Y, Kong D, Ahmad A, Bao B, Sarkar FH. Pancreatic cancer stem cells: Emerging target for designing novel therapy. Cancer Lett  2013; 338(1): 94-100.
 [http://dx.doi.org/10.1016/j.canlet.2012.03.018] [PMID:  22445908]

[68]
Abel EV, Goto M, Magnuson B, et al. HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties. eLife  2018; 7: e33947.
 [http://dx.doi.org/10.7554/eLife.33947] [PMID:  30074477]

[69]
Zhu YY, Yuan Z. Pancreatic cancer stem cells. Am J Cancer Res  2015; 5(3): 894-906.
 [PMID:  26045976]

[70]
Abel EV, Simeone DM. Biology and clinical applications of pancreatic cancer stem cells. Gastroenterology  2013; 144(6): 1241-8.
 [http://dx.doi.org/10.1053/j.gastro.2013.01.072] [PMID:  23622133]

[71]
Hermann PC, Sainz B Jr. Pancreatic cancer stem cells: A state or an entity? Semin Cancer Biol  2018; 53: 223-31.
 [http://dx.doi.org/10.1016/j.semcancer.2018.08.007] [PMID:  30130664]

[72]
Rao CV, Mohammed A. New insights into pancreatic cancer stem cells. World J Stem Cells  2015; 7(3): 547-55.
 [http://dx.doi.org/10.4252/wjsc.v7.i3.547] [PMID:  25914762]

[73]
Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J Clin Oncol  2008; 26(17): 2806-12.
 [http://dx.doi.org/10.1200/JCO.2008.16.6702] [PMID:  18539958]

[74]
Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell  2007; 1(3): 313-23.
 [http://dx.doi.org/10.1016/j.stem.2007.06.002] [PMID:  18371365]

[75]
English DP, Roque DM, Santin AD. HER2 expression beyond breast cancer: Therapeutic implications for gynecologic malignancies. Mol Diagn Ther  2013; 17(2): 85-99.
 [http://dx.doi.org/10.1007/s40291-013-0024-9] [PMID:  23529353]

[76]
Momeny M, Esmaeili F, Hamzehlou S, et al. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells. Cell Oncol  2019; 42(4): 491-504.
 [http://dx.doi.org/10.1007/s13402-019-00448-w] [PMID:  31025257]

[77]
Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer  2002; 38 (Suppl. 5): S3-S10.

[78]
Butti R, Das S, Gunasekaran VP, Yadav AS, Kumar D, Kundu GC. Receptor tyrosine kinases (RTKs) in breast cancer: Signaling, therapeutic implications and challenges. Mol Cancer  2018; 17(1): 34.
 [http://dx.doi.org/10.1186/s12943-018-0797-x] [PMID:  29455658]

[79]
Garcia-Sampedro A, Gaggia G, Ney A, Mahamed I, Acedo P. The state-of-the-art of phase II/III clinical trials for targeted pancreatic cancer therapies. J Clin Med  2021; 10(4): 566.
 [http://dx.doi.org/10.3390/jcm10040566] [PMID:  33546207]

[80]
Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Rüttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer  2017; 5(1): 53.
 [http://dx.doi.org/10.1186/s40425-017-0257-y] [PMID:  28716061]

[81]
Wang-Gillam A, O’Reilly EM, Bendell JC, et al. A randomized phase II study of cabiralizumab (cabira) + nivolumab (nivo) ± chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC). Am Soc Clin Oncol  2019; 37(4)
 [http://dx.doi.org/10.1200/JCO.2019.37.4_suppl.TPS465]

[82]
Bousquet C, Puente E, Buscail L, Vaysse N, Susini C. Antiproliferative effect of somatostatin and analogs. Chemotherapy  2001; 47 (Suppl. 2): 30-9.
 [http://dx.doi.org/10.1159/000049159] [PMID:  11275700]

[83]
Dreyer SB, Chang DK, Bailey P, Biankin AV. Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development. Clin Cancer Res  2017; 23(7): 1638-46.
 [http://dx.doi.org/10.1158/1078-0432.CCR-16-2411] [PMID:  28373362]

[84]
Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature  2015; 518(7540): 495-501.
 [http://dx.doi.org/10.1038/nature14169] [PMID:  25719666]

[85]
Kasi A, Chalise P, Williamson SK, et al. Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): A phase 2 trial. Am Soc Clin Oncol  2019; 37(15)

[86]
Piao J, Zhu L, Sun J, et al. High expression of CDK1 and BUB1 predicts poor prognosis of pancreatic ductal adenocarcinoma. Gene  2019; 701: 15-22.
 [http://dx.doi.org/10.1016/j.gene.2019.02.081] [PMID:  30898709]

[87]
Chu QS, Jonker DJ, Provencher DM, et al. A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Am Soc Clin Oncol  2020; 37(15)
 [http://dx.doi.org/10.1200/JCO.2020.38.15_suppl.3581]

[88]
Deryugina EI, Quigley JP. Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biol  2015; 44-46: 94-112.

[89]
Li S, Xu HX, Wu CT, et al. Angiogenesis in pancreatic cancer: Current research status and clinical implications. Angiogenesis  2019; 22(1): 15-36.
 [http://dx.doi.org/10.1007/s10456-018-9645-2] [PMID:  30168025]

[90]
Rosen LS, Jacobs IA, Burkes RL. Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Target Oncol  2017; 12(5): 599-610.
 [http://dx.doi.org/10.1007/s11523-017-0518-1] [PMID:  28801849]

[91]
Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol  2009; 27(13): 2231-7.
 [http://dx.doi.org/10.1200/JCO.2008.20.0238] [PMID:  19307500]

[92]
Luedke E, Jaime-Ramirez AC, Bhave N, Carson W. E 3rd. Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation. J Immunother  2012; 35(5): 367-73.

[93]
Tiong KH, Mah LY, Leong CO. Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. Apoptosis  2013; 18(12): 1447-68.

[94]
Wong KK. DNMT1 as a therapeutic target in pancreatic cancer: Mechanisms and clinical implications. Cell Oncol (Dordr)  2020; 43(5): 779-92.
 [http://dx.doi.org/10.1007/s13402-020-00526-4] [PMID:  32504382]

[95]
Proia TA, Singh M, Woessner R, et al. STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1. Clin Cancer Res  2020; 26(23): 6335-49.
 [http://dx.doi.org/10.1158/1078-0432.CCR-20-1066] [PMID:  32943458]

[96]
Bekaii-Saab TS, Mikhail S, Langleben A, et al. A phase Ib/II study of BBI608 combined with weekly paclitaxel in advanced pancreatic cancer. Am Soc Clin Oncol  2016; 38(15)
 [http://dx.doi.org/10.1200/jco.2016.34.4_suppl.196]

[97]
Coulombe P, Meloche S. Atypical mitogen-activated protein kinases: Structure, regulation and functions. Biochim Biophys Acta Mol Cell Res  2007; 1773(8): 1376-87.
 [http://dx.doi.org/10.1016/j.bbamcr.2006.11.001] [PMID:  17161475]

[98]
Drosten M, Barbacid M. Targeting the MAPK Pathway in KRAS-Driven Tumors. Cancer Cell  2020; 37(4): 543-50.
 [http://dx.doi.org/10.1016/j.ccell.2020.03.013] [PMID:  32289276]

[99]
Bryant KL, Stalnecker CA, Zeitouni D, et al. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med  2019; 25(4): 628-40.
 [http://dx.doi.org/10.1038/s41591-019-0368-8] [PMID:  30833752]

[100]
Sullivan RJ, Infante JR, Janku F, et al. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discov  2018; 8(2): 184-95.
 [http://dx.doi.org/10.1158/2159-8290.CD-17-1119] [PMID:  29247021]

[101]
Caunt CJ, Sale MJ, Smith PD, Cook SJ. MEK1 and MEK2 inhibitors and cancer therapy: The long and winding road. Nat Rev Cancer  2015; 15(10): 577-92.
 [http://dx.doi.org/10.1038/nrc4000] [PMID:  26399658]

[102]
Garnock-Jones KP. Cobimetinib: First Global Approval. Drugs  2015; 75(15): 1823-30.
 [http://dx.doi.org/10.1007/s40265-015-0477-8] [PMID:  26452567]

[103]
Ryan MB, Corcoran RB. Therapeutic strategies to target RAS-mutant cancers. Nat Rev Clin Oncol  2018; 15(11): 709-20.
 [http://dx.doi.org/10.1038/s41571-018-0105-0] [PMID:  30275515]

[104]
Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev  2006; 20(10): 1218-49.
 [http://dx.doi.org/10.1101/gad.1415606] [PMID:  16702400]

[105]
Kosmidis C, Sapalidis K, Kotidis E, et al. Pancreatic cancer from bench to bedside: Molecular pathways and treatment options. Ann Transl Med  2016; 4(9): 165.
 [http://dx.doi.org/10.21037/atm.2016.05.11] [PMID:  27275478]

[106]
Ishii H, Furuse J, Nagase M, Yoshino M. Impact of gemcitabine on the treatment of metastatic pancreatic cancer. J Gastroenterol Hepatol  2005; 20(1): 62-6.
 [http://dx.doi.org/10.1111/j.1440-1746.2004.03487.x] [PMID:  15610448]

[107]
Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Büchler MW. Advanced-stage pancreatic cancer: Therapy options. Nat Rev Clin Oncol  2013; 10(6): 323-33.
 [http://dx.doi.org/10.1038/nrclinonc.2013.66] [PMID:  23629472]

[108]
Adamska A, Elaskalani O, Emmanouilidi A, et al. Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. Adv Biol Regul  2018; 68: 77-87.
 [http://dx.doi.org/10.1016/j.jbior.2017.11.007] [PMID:  29221990]

[109]
Zhang Q, Zeng L, Chen Y, et al. Pancreatic Cancer Epidemiology, Detection, and Management. Gastroenterol Res Pract  2016; 2016: 1-10.
 [http://dx.doi.org/10.1155/2016/8962321] [PMID:  26941789]

[110]
Simeone DM, Ji B, Banerjee M, et al. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas  2007; 34(4): 436-43.
 [http://dx.doi.org/10.1097/MPA.0b013e3180333ae3] [PMID:  17446843]

[111]
Strobel O, Neoptolemos J, Jäger D, Büchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol  2019; 16(1): 11-26.
 [http://dx.doi.org/10.1038/s41571-018-0112-1] [PMID:  30341417]

[112]
Hackert T, Klaiber U, Pausch T, Mihaljevic AL, Büchler MW. Fifty Years of Surgery for Pancreatic Cancer. Pancreas  2020; 49(8): 1005-13.
 [http://dx.doi.org/10.1097/MPA.0000000000001634] [PMID:  32833940]

[113]
Loos M, Kleeff J, Friess H, Büchler MW. Surgical treatment of pancreatic cancer. Ann N Y Acad Sci  2008; 1138(1): 169-80.
 [http://dx.doi.org/10.1196/annals.1414.024] [PMID:  18837898]

[114]
Bakens MJ, Geest LG, Putten M, et al. The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: A nationwide population-based analysis. Cancer Med  2016; 5(10): 2825-31.
 [http://dx.doi.org/10.1002/cam4.921] [PMID:  27671746]

[115]
Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: Current and future perspectives. Nat Rev Gastroenterol Hepatol  2018; 15(6): 333-48.
 [http://dx.doi.org/10.1038/s41575-018-0005-x] [PMID:  29717230]

[116]
Kolbeinsson HM, Chandana S, Wright GP, Chung M. Pancreatic cancer: A review of current treatment and novel therapies. J Invest Surg  2023; 36(1): 2129884.
 [http://dx.doi.org/10.1080/08941939.2022.2129884] [PMID:  36191926]

[117]
Lin H-C, Shih Y-H. Adjuvant gemcitabine+ S1 as adjuvant therapy for resectable pancreatic cancer: A real-world experience in a single-center retrospective study. Am Soc Clin Oncol  2023; 41(4)

[118]
Verma V, Li J, Lin C. Neoadjuvant Therapy for Pancreatic Cancer. Am J Clin Oncol  2016; 39(3): 302-13.
 [http://dx.doi.org/10.1097/COC.0000000000000278] [PMID:  26950464]

[119]
Xu X, Wu Q, Wang Z, Zheng S, Ge K, Jia C. Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer. Clin Exp Med  2019; 19(1): 149-57.
 [http://dx.doi.org/10.1007/s10238-018-0540-3] [PMID:  30498929]

[120]
Springfeld C, Ferrone CR, Katz MHG, et al. Neoadjuvant therapy for pancreatic cancer. Nat Rev Clin Oncol  2023; 20(5): 318-37.
 [http://dx.doi.org/10.1038/s41571-023-00746-1] [PMID:  36932224]

[121]
de Geus SWL, Sachs TE. A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer. Ann Surg Oncol  2023; 30(6): 3427-36.
 [http://dx.doi.org/10.1245/s10434-023-13281-1] [PMID:  36869916]

[122]
Springfeld C, Jäger D, Büchler MW, et al. Chemotherapy for pancreatic cancer. Presse medicale  2019; 48(Pt 2): e159-74.

[123]
Williet N, Saint A, Pointet AL, et al. Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: A comparative propensity score study. Therap Adv Gastroenterol  2019; 12.
 [http://dx.doi.org/10.1177/1756284819878660] [PMID:  31598136]

[124]
Güngör C, Hofmann BT, Wolters-Eisfeld G, Bockhorn M. Pancreatic cancer. Br J Pharmacol  2014; 171(4): 849-58.
 [http://dx.doi.org/10.1111/bph.12401] [PMID:  24024905]

[125]
Mancuso A, Calabrò F, Sternberg CN. Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol  2006; 58(3): 231-41.
 [http://dx.doi.org/10.1016/j.critrevonc.2006.02.004] [PMID:  16725343]

[126]
Saung MT, Zheng L. Current Standards of Chemotherapy for Pancreatic Cancer. Clin Ther  2017; 39(11): 2125-34.
 [http://dx.doi.org/10.1016/j.clinthera.2017.08.015] [PMID:  28939405]

[127]
Karasic TB, O’Hara MH, Loaiza-Bonilla A, et al. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer. JAMA Oncol  2019; 5(7): 993-8.
 [http://dx.doi.org/10.1001/jamaoncol.2019.0684] [PMID:  31120501]

[128]
Zeh HJ, Bahary N, Boone BA, et al. A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Clin Cancer Res  2020; 26(13): 3126-34.
 [http://dx.doi.org/10.1158/1078-0432.CCR-19-4042] [PMID:  32156749]

[129]
Cho IR, Kang H, Jo JH, et al. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. World J Gastrointest Oncol  2020; 12(2): 182-94.
 [http://dx.doi.org/10.4251/wjgo.v12.i2.182] [PMID:  32104549]

[130]
Goldstein D, El-Maraghi RH, Hammel P, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: Long-term survival from a phase III trial. J Natl Cancer Inst  2015; 107(2): dju413.
 [http://dx.doi.org/10.1093/jnci/dju413] [PMID:  25638248]

[131]
Chiorean EG, Cheung WY, Giordano G, Kim G, Al-Batran SE. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: A systematic review. Ther Adv Med Oncol  2019; 11.
 [http://dx.doi.org/10.1177/1758835919850367] [PMID:  31205510]

[132]
Schlick K, Magnes T, Ratzinger L, et al. Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters. PLoS One  2018; 13(11): e0206688.
 [http://dx.doi.org/10.1371/journal.pone.0206688] [PMID:  30412592]

[133]
Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: A systematic review and patient-level meta-analysis. Lancet Oncol  2016; 17(6): 801-10.
 [http://dx.doi.org/10.1016/S1470-2045(16)00172-8] [PMID:  27160474]

[134]
Pusceddu S, Ghidini M, Torchio M, et al. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel)  2019; 11(4): 484.
 [http://dx.doi.org/10.3390/cancers11040484] [PMID:  30959763]

[135]
Sawada M, Kasuga A, Mie T, et al. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. BMC Cancer  2020; 20(1): 449.
 [http://dx.doi.org/10.1186/s12885-020-06945-8] [PMID:  32434547]

[136]
Kieler M, Unseld M, Bianconi D, Scheithauer W, Prager GW. A real-world analysis of second-line treatment options in pancreatic cancer: Liposomal-irinotecan plus 5-fluorouracil and folinic acid. Ther Adv Med Oncol  2019; 11.
 [http://dx.doi.org/10.1177/1758835919853196] [PMID:  31360237]

[137]
Aprile G, Negri FV, Giuliani F, et al. Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? Crit Rev Oncol Hematol  2017; 115: 1-12.
 [http://dx.doi.org/10.1016/j.critrevonc.2017.03.025] [PMID:  28602164]

[138]
Hammel P, Fabienne P, Mineur L, et al. Erratum to ‘Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial’. Eur J Cancer  2020; 130: 275-6.

[139]
Kobayashi N, Shimamura T, Tokuhisa M, Goto A, Endo I, Ichikawa Y. Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure. Medicine (Baltimore)  2017; 96(19): e6769.
 [http://dx.doi.org/10.1097/MD.0000000000006769] [PMID:  28489753]

[140]
Cantore M, Rabbi C, Fiorentini G, et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology  2004; 67(2): 93-7.
 [http://dx.doi.org/10.1159/000080993] [PMID:  15539911]

[141]
Zishan M, Saidurrahman S, Anayatullah A, Azeemuddin A, Ahmad Z, Hussain MW. Natural products used as anti-cancer agents. J Drug Deliv Ther  2017; 7(3): 11-8.
 [http://dx.doi.org/10.22270/jddt.v7i3.1443]

[142]
Safe S, Kasiappan R. Natural Products as Mechanism-based Anticancer Agents: Sp Transcription Factors as Targets. Phytother Res  2016; 30(11): 1723-32.
 [http://dx.doi.org/10.1002/ptr.5669] [PMID:  27384261]

[143]
Bimonte S, Barbieri A, Leongito M, et al. Curcumin AntiCancer Studies in Pancreatic Cancer. Nutrients  2016; 8(7): 433.
 [http://dx.doi.org/10.3390/nu8070433] [PMID:  27438851]

[144]
Son YO, Kim J, Lim JC, Chung Y, Chung GH, Lee JC. Ripe fruit of Solanum nigrum L. inhibits cell growth and induces apoptosis in MCF-7 cells. Food Chem Toxicol  2003; 41(10): 1421-8.

[145]
Kingston DGI. The shape of things to come: Structural and synthetic studies of taxol and related compounds. Phytochemistry  2007; 68(14): 1844-54.
 [http://dx.doi.org/10.1016/j.phytochem.2006.11.009] [PMID:  17184797]

[146]
Hait WN, Rubin E, Alli E, Goodin S. Tubulin targeting agents. Update Cancer Ther  2007; 2(1): 1-18.
 [http://dx.doi.org/10.1016/j.uct.2006.10.001]

[147]
Hussain H, Green IR, Saleem M, Khattak KF, Irshad M, Ali M. Cucurbitacins as Anticancer Agents: A Patent Review. Recent Patents Anticancer Drug Discov  2019; 14(2): 133-43.
 [http://dx.doi.org/10.2174/1574892813666181119123035] [PMID:  30451116]

[148]
Wang F, Gao Y, Gao L, Xing T. Study on the electrochemical behavior of the anticancer herbal drug berberine and its analytical application. J Chin Chem Soc (Taipei)  2011; 58(4): 450-6.
 [http://dx.doi.org/10.1002/jccs.201190005]

[149]
Kaschula CH, Hunter R, Parker MI. Garlic-derived anticancer agents: Structure and biological activity of ajoene. (Biofactors)2010; 36(1) NA. http://dx.doi.org/10.1002/biof.76 PMID: 20108330

[150]
Nouroz F, Mehboob M, Noreen S, Zaidi F, Mobin T. A review on anticancer activities of garlic (Allium sativum L.). Middle East J Sci Res  2015; 23(6): 1145-51.

[151]
Birbrair A, Zhang T, Wang ZM, Messi ML, Mintz A, Delbono O. Pericytes: Multitasking cells in the regeneration of injured, diseased, and aged skeletal muscle. Front Aging Neurosci  2014; 6: 245.
 [http://dx.doi.org/10.3389/fnagi.2014.00245] [PMID:  25278877]

[152]
Xu B, Li C, Sung C. Telomerase inhibitory effects of medicinal mushrooms and lichens, and their anticancer activity. Int J Med Mushrooms  2014; 16(1): 17-28.
 [http://dx.doi.org/10.1615/IntJMedMushr.v16.i1.20] [PMID:  24940901]

[153]
Buyel JF. Plants as sources of natural and recombinant anti-cancer agents. Biotechnol Adv  2018; 36(2): 506-20.
 [http://dx.doi.org/10.1016/j.biotechadv.2018.02.002] [PMID:  29408560]

[154]
Vandenborre G, Smagghe G, Van Damme EJM. Plant lectins as defense proteins against phytophagous insects. Phytochemistry  2011; 72(13): 1538-50.
 [http://dx.doi.org/10.1016/j.phytochem.2011.02.024] [PMID:  21429537]

[155]
Fahy J. Modifications in the “upper” velbenamine part of the Vinca alkaloids have major implications for tubulin interacting activities. Curr Pharm Des  2001; 7(13): 1181-97.
 [http://dx.doi.org/10.2174/1381612013397483] [PMID:  11472261]

[156]
Yun-San Yip A, Yuen-Yuen Ong E, Chow LWC. Vinflunine: Clinical perspectives of an emerging anticancer agent. Expert Opin Investig Drugs  2008; 17(4): 583-91.
 [http://dx.doi.org/10.1517/13543784.17.4.583] [PMID:  18363522]

[157]
Nobili S, Lippi D, Witort E, et al. Natural compounds for cancer treatment and prevention. Pharmacol Res  2009; 59(6): 365-78.
 [http://dx.doi.org/10.1016/j.phrs.2009.01.017] [PMID:  19429468]

[158]
Schellens JH, McLeod HL, Newell DR. Cancer clinical pharmacology. United Kingdom: Oxford University Press 2005.

[159]
Prakash O, Kumar A, Kumar P, Ajeet A. Anticancer potential of plants and natural products. Am J Pharmacol Sci  2013; 1(6): 104-15.
 [http://dx.doi.org/10.12691/ajps-1-6-1]

[160]
Nam NH. Combretastatin A-4 analogues as antimitotic antitumor agents. Curr Med Chem  2003; 10(17): 1697-722.
 [http://dx.doi.org/10.2174/0929867033457151] [PMID:  12871118]

[161]
Blagosklonny MV. Flavopiridol, an inhibitor of transcription: Implications, problems and solutions. Cell Cycle  2004; 3(12): 1537-42.
 [http://dx.doi.org/10.4161/cc.3.12.1278] [PMID:  15539947]

[162]
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: Problems and promises. Mol Pharm  2007; 4(6): 807-18.
 [http://dx.doi.org/10.1021/mp700113r] [PMID:  17999464]

[163]
Hewlings S, Kalman D. Curcumin: A Review of Its Effects on Human Health. Basel, Switzerland: Foods 2017.

[164]
Nagaraju GP, Benton L, Bethi SR, Shoji M, El-Rayes BF. Curcumin analogs: Their roles in pancreatic cancer growth and metastasis. Int J Cancer  2019; 145(1): 10-9.
 [http://dx.doi.org/10.1002/ijc.31867] [PMID:  30226272]

[165]
Agrawal DK, Mishra PK. Curcumin and its analogues: Potential anticancer agents. Med Res Rev  2010; 30(5): 818-60.
 [PMID:  20027668]

[166]
Zhao C, Liu Z, Liang G. Promising curcumin-based drug design: Mono-carbonyl analogues of curcumin (MACs). Curr Pharm Des  2013; 19(11): 2114-35.
 [PMID:  23116317]

[167]
Ohori H, Yamakoshi H, Tomizawa M, et al. Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther  2006; 5(10): 2563-71.
 [http://dx.doi.org/10.1158/1535-7163.MCT-06-0174] [PMID:  17041101]

[168]
Nagaraju GP, Zhu S, Wen J, et al. Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer. Cancer Lett  2013; 341(2): 195-203.
 [http://dx.doi.org/10.1016/j.canlet.2013.08.002] [PMID:  23933177]

[169]
Friedman L, Lin L, Ball S, et al. Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells. Anticancer Drugs  2009; 20(6): 444-9.
 [http://dx.doi.org/10.1097/CAD.0b013e32832afc04] [PMID:  19384191]

[170]
Nagaraju GP, Zhu S, Ko JE, et al. Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer. Cancer Lett  2015; 357(2): 557-65.
 [http://dx.doi.org/10.1016/j.canlet.2014.12.007] [PMID:  25497868]

[171]
Zhu Y, Bu S. Curcumin induces autophagy, apoptosis, and cell cycle arrest in human pancreatic cancer cells. Evid Based Complement Alternat Med  2017; 2017: 5787218.

[172]
Sa G, Das T. Anti cancer effects of curcumin: Cycle of life and death. Cell Div  2008; 3(1): 14.
 [http://dx.doi.org/10.1186/1747-1028-3-14] [PMID:  18834508]

[173]
He Y, Yue Y, Zheng X, Zhang K, Chen S, Du Z. Curcumin, inflammation, and chronic diseases: How are they linked? Molecules  2015; 20(5): 9183-213.
 [http://dx.doi.org/10.3390/molecules20059183] [PMID:  26007179]

[174]
Campbell FC, Collett GP. Chemopreventive properties of curcumin. Future Oncol  2005; 1(3): 405-14.
 [http://dx.doi.org/10.1517/14796694.1.3.405] [PMID:  16556014]

[175]
Surh YJ, Chun KS. Cancer chemopreventive effects of curcumin. Adv Exp Med Biol  2007; 595: 149-72.
 [http://dx.doi.org/10.1007/978-0-387-46401-5_5] [PMID:  17569209]

[176]
Jadid MFS, Shademan B, Chavoshi R, et al. Enhanced anticancer potency of hydroxytyrosol and curcumin by PLGA-PAA nano-encapsulation on PANC -1 pancreatic cancer cell line. Environ Toxicol  2021; 36(6): 1043-51.
 [http://dx.doi.org/10.1002/tox.23103] [PMID:  33496383]

[177]
Boyanapalli SSS, Kong ANT. “Curcumin, the King of Spices”: Epigenetic Regulatory Mechanisms in the Prevention of Cancer, Neurological, and Inflammatory Diseases. Curr Pharmacol Rep  2015; 1(2): 129-39.
 [http://dx.doi.org/10.1007/s40495-015-0018-x] [PMID:  26457241]

[178]
Chiang T, Wang WS, Liu HC, Yang ST, Tang NY, Chung JG. Curcumin alters gene expression-associated DNA damage, cell cycle, cell survival and cell migration and invasion in NCI-H460 human lung cancer cells in vitro. Oncol Rep  2015; 34(4): 1853-74.
 [http://dx.doi.org/10.3892/or.2015.4159] [PMID:  26238775]

[179]
Shehzad A, Qureshi M, Anwar MN, Lee YS. Multifunctional Curcumin Mediate Multitherapeutic Effects. J Food Sci  2017; 82(9): 2006-15.
 [http://dx.doi.org/10.1111/1750-3841.13793] [PMID:  28771714]

[180]
Youns M, Fathy GM. Upregulation of extrinsic apoptotic pathway in curcumin-mediated antiproliferative effect on human pancreatic carcinogenesis. J Cell Biochem  2013; 114(12): 2654-65.
 [http://dx.doi.org/10.1002/jcb.24612] [PMID:  23794119]

[181]
Glienke W, Maute L, Wicht J, Bergmann L. Curcumin inhibits constitutive STAT3 phosphorylation in human pancreatic cancer cell lines and downregulation of survivin/BIRC5 gene expression. Cancer Invest  2009; 28(2): 166-71.
 [http://dx.doi.org/10.3109/07357900903287006] [PMID:  20121547]

[182]
Glienke W, Maute L, Wicht J, Bergmann L. Wilms’ tumour gene 1 (WT1) as a target in curcumin treatment of pancreatic cancer cells. Eur J Cancer  2009; 45(5): 874-0.

[183]
Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett  2008; 269(2): 199-225.
 [http://dx.doi.org/10.1016/j.canlet.2008.03.009] [PMID:  18479807]

[184]
Swamy MV, Citineni B, Patlolla JMR, Mohammed A, Zhang Y, Rao CV. Prevention and treatment of pancreatic cancer by curcumin in combination with omega-3 fatty acids. Nutr Cancer  2008; 60 ((sup1)(Suppl. 1)): 81-9.
 [http://dx.doi.org/10.1080/01635580802416703] [PMID: 19003584]

[185]
Dende C, Meena J, Nagarajan P, Nagaraj VA, Panda AK, Padmanaban G. Nanocurcumin is superior to native curcumin in preventing degenerative changes in Experimental Cerebral Malaria. Sci Rep  2017; 7(1): 10062.
 [http://dx.doi.org/10.1038/s41598-017-10672-9] [PMID:  28855623]

[186]
Yallapu MM, Nagesh PKB, Jaggi M, Chauhan SC. Therapeutic Applications of Curcumin Nanoformulations. AAPS J  2015; 17(6): 1341-56.
 [http://dx.doi.org/10.1208/s12248-015-9811-z] [PMID:  26335307]

[187]
Islam A, Rebello L, Chepyala S. Review on nanoformulations of curcumin (Curcuma longa Linn.): Special emphasis on Nanocurcumin®. Int J Nat Life Sci  2019; 3(1): 1-12.

[188]
Al-Shehri H. The Nanoformulations of Curcumin for Cancer Therapy: New Perspectives. J Cancer Res Treat  2019; 7(1): 21-6.

[189]
Rachmawati H, Yanda YL, Rahma A, Mase N, Curcumin-Loaded PLA. Curcumin-Loaded PLA Nanoparticles: Formulation and Physical Evaluation. Sci Pharm  2016; 84(1): 191-202.
 [http://dx.doi.org/10.3797/scipharm.ISP.2015.10] [PMID:  27110509]

[190]
Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci  2010; 351(1): 19-29.
 [http://dx.doi.org/10.1016/j.jcis.2010.05.022] [PMID:  20627257]

[191]
Al-Shehri AH, Kabel AM, Abd Elmaaboud MA. The Nanoformulations of Curcumin for Cancer Therapy: New Perspectives. J Cancer Res  2019; 7(1): 21-6.

[192]
Orr WS, Denbo JW, Saab KR, et al. RETRACTED: Liposome-encapsulated curcumin suppresses neuroblastoma growth through nuclear factor-kappa B inhibition. Surgery  2012; 151(5): 736-44.
 [http://dx.doi.org/10.1016/j.surg.2011.12.014] [PMID:  22284765]

[193]
Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin. Cancer  2005; 104(6): 1322-31.
 [http://dx.doi.org/10.1002/cncr.21300] [PMID:  16092118]

[194]
Barui S, Saha S, Yakati V, Chaudhuri A. Systemic Codelivery of a Homoserine Derived Ceramide Analogue and Curcumin to Tumor Vasculature Inhibits Mouse Tumor Growth. Mol Pharm  2016; 13(2): 404-19.
 [http://dx.doi.org/10.1021/acs.molpharmaceut.5b00644] [PMID:  26716471]

[195]
Lee WH, Loo CY, Young PM, Traini D, Mason RS, Rohanizadeh R. Recent advances in curcumin nanoformulation for cancer therapy. Expert Opin Drug Deliv  2014; 11(8): 1183-201.
 [http://dx.doi.org/10.1517/17425247.2014.916686] [PMID:  24857605]

[196]
Yallapu MM, Jaggi M, Chauhan SC. Poly(β-cyclodextrin)/curcumin self-assembly: A novel approach to improve curcumin delivery and its therapeutic efficacy in prostate cancer cells. Macromol Biosci  2010; 10(10): 1141-51.
 [http://dx.doi.org/10.1002/mabi.201000084] [PMID:  20572274]

[197]
Subramani PA, Panati K, Narala VR. Curcumin Nanotechnologies and Its Anticancer Activity. Nutr Cancer  2017; 69(3): 381-93.
 [http://dx.doi.org/10.1080/01635581.2017.1285405] [PMID:  28287321]

[198]
Mangalathillam S, Rejinold NS, Nair A, Lakshmanan VK, Nair SV, Jayakumar R. Curcumin loaded chitin nanogels for skin cancer treatment via the transdermal route. Nanoscale  2012; 4(1): 239-50.
 [http://dx.doi.org/10.1039/C1NR11271F] [PMID:  22080352]

[199]
Yallapu MM, Ebeling MC, Khan S, et al. Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Mol Cancer Ther  2013; 12(8): 1471-80.
 [http://dx.doi.org/10.1158/1535-7163.MCT-12-1227] [PMID:  23704793]

[200]
Sheikh E, Bhatt M, Tripathi M. Role of nano-curcumin: A treatment for cancer. Faslnamah-i Giyahan-i Daruyi  2017; 5: 394-7.
Rights & Permissions Print Cite
Article Metrics
24
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1573394719666230830125213	Print ISSN 1573-3947
Publisher Name Bentham Science Publisher	Online ISSN 1875-6301
Current Cancer Therapy Reviews

Pancreatic Cancer: A Review on Pathophysiology, Naturopathy, Clinical Treatment and Outcomes

Abstract

Graphical Abstract

Related Journals

Related Books
